Literature DB >> 15999057

Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer.

Kimihiro Shimizu1, Junji Yoshida, Kanji Nagai, Mitsuyo Nishimura, Genichiro Ishii, Yasuo Morishita, Yutaka Nishiwaki.   

Abstract

OBJECTIVE: Although visceral pleural invasion by non-small cell lung cancer is considered a poor-prognostic factor, further information is lacking, especially in relation to other clinicopathologic prognostic factors. We assessed the relationship between visceral pleural invasion and other clinicopathologic characteristics and evaluated its significance as a prognostic factor.
METHODS: We reviewed 1074 patients with surgically resected T1/2 non-small cell lung cancer for their clinicopathologic characteristics and prognoses. The patients were divided into 2 groups according to visceral pleural invasion status (visceral pleural invasion group and non-visceral pleural invasion group). Both groups were compared with regard to age, sex, histology, tumor size, tumor differentiation, lymph node involvement, lymphatic invasion, vascular invasion, scar grade, nuclear atypia, mitotic index, serum carcinoembryonic antigen level, and survival. Univariate and multivariate analyses were conducted.
RESULTS: Visceral pleural invasion was identified in 288 (26.8%) of the resected specimens. Survival was 76.0% at 5 years and 53.2% at 10 years in the non-visceral pleural invasion group and was 49.8% at 5 years and 37.0% at 10 years in the visceral pleural invasion group. The difference between groups was highly significant ( P < .0001). Visceral pleural invasion was also significantly associated with a higher frequency of lymph node involvement. However, regardless of N status (N0 or N1/2), there was a significant difference in survival when the visceral pleura was invaded. Visceral pleural invasion was observed significantly more frequently in tumors with factors indicative of tumor aggressiveness/invasiveness: moderate/poor differentiation, lymphatic invasion, vascular invasion, high scar grade, high nuclear atypia grade, high mitotic index, and high serum carcinoembryonic antigen level. By multivariate analysis, visceral pleural invasion proved to be a significant independent predictor of poor prognosis in non-small-cell lung cancer patients with or without lymph node involvement.
CONCLUSIONS: Visceral pleural invasion is a significant poor-prognostic factor, regardless of N status. Our analyses indicated that visceral pleural invasion is an independent indicator of non-small cell lung cancer invasiveness and aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15999057     DOI: 10.1016/j.jtcvs.2004.11.021

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  55 in total

1.  Validity of using lobe-specific regional lymph node stations to assist navigation during lymph node dissection in early stage non-small cell lung cancer patients.

Authors:  Shinichiro Miyoshi; Kazuhiko Shien; Shinichi Toyooka; Kentaroh Miyoshi; Hiromasa Yamamoto; Seiichiro Sugimoto; Junichi Soh; Makio Hayama; Masaomi Yamane; Takahiro Oto
Journal:  Surg Today       Date:  2013-10-31       Impact factor: 2.549

2.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

3.  Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study.

Authors:  Li-Lan Zhao; Hui-Kang Xie; Li-Ping Zhang; Jun-Yan Zha; Fang-Yu Zhou; Ge-Ning Jiang; Chang Chen
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  CT diagnosis of pleural and stromal invasion in malignant subpleural pure ground-glass nodules: an exploratory study.

Authors:  Qing Zhao; Jian-Wei Wang; Lin Yang; Li-Yan Xue; Wen-Wen Lu
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

5.  Risk of pleural recurrence after percutaneous transthoracic needle biopsy in stage I non-small-cell lung cancer.

Authors:  Su Yeon Ahn; Soon Ho Yoon; Bo Ram Yang; Young Tae Kim; Chang Min Park; Jin Mo Goo
Journal:  Eur Radiol       Date:  2018-06-15       Impact factor: 5.315

6.  Spread through air spaces-novel pattern of cancer progression.

Authors:  Satoshi Shiono
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

7.  Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.

Authors:  Juheon Lee; Yi Cui; Xiaoli Sun; Bailiang Li; Jia Wu; Dengwang Li; Michael F Gensheimer; Billy W Loo; Maximilian Diehn; Ruijiang Li
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

8.  Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer.

Authors:  Yasuaki Kubouchi; Yoshiteru Kidokoro; Takashi Ohno; Yohei Yurugi; Makoto Wakahara; Tomohiro Haruki; Hiroshige Nakamura
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

9.  Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set.

Authors:  Juan J Fibla; Stephen D Cassivi; Alessandro Brunelli; Paul A Decker; Mark S Allen; Gail E Darling; Rodney J Landreneau; Joe B Putnam
Journal:  Lung Cancer       Date:  2012-10-03       Impact factor: 5.705

10.  Invasion of the inner and outer layers of the visceral pleura in pT1 size lung adenocarcinoma measuring ≤ 3 cm: correlation with malignant aggressiveness and prognosis.

Authors:  Makoto Hamasaki; Fumiaki Kato; Kaori Koga; Hiroyuki Hayashi; Mikiko Aoki; Yoshihiro Miyake; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Virchows Arch       Date:  2012-09-22       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.